Tempus AI (NASDAQ:TEM) Given New $70.00 Price Target at Morgan Stanley

Tempus AI (NASDAQ:TEM) had its price target trimmed by Morgan Stanley from $85.00 to $70.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other brokerages have also weighed in on TEM. Needham & Company LLC decreased their price objective on shares of Tempus AI from $100.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research reduced their target price on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Canaccord Genuity Group lowered their price target on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. Finally, Robert W. Baird began coverage on Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $78.15.

Tempus AI Stock Down 3.6%

NASDAQ:TEM opened at $51.40 on Tuesday. The company has a market cap of $9.14 billion, a price-to-earnings ratio of -36.45 and a beta of 5.29. Tempus AI has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a current ratio of 3.13, a quick ratio of 3.00 and a debt-to-equity ratio of 2.52. The stock has a fifty day simple moving average of $60.83 and a 200-day simple moving average of $73.07.

Insiders Place Their Bets

In other news, CAO Ryan M. Bartolucci sold 2,902 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $171,363.10. Following the completion of the sale, the chief accounting officer owned 41,159 shares of the company’s stock, valued at approximately $2,430,438.95. This represents a 6.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Andrew Polovin sold 10,949 shares of Tempus AI stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19. Following the transaction, the executive vice president directly owned 126,918 shares in the company, valued at approximately $7,654,424.58. The trade was a 7.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 590,109 shares of company stock worth $37,056,566. 26.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently made changes to their positions in TEM. Caitong International Asset Management Co. Ltd boosted its position in Tempus AI by 38,059.2% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 27,093 shares of the company’s stock valued at $1,600,000 after purchasing an additional 27,022 shares in the last quarter. Virtu Financial LLC lifted its position in shares of Tempus AI by 384.6% during the fourth quarter. Virtu Financial LLC now owns 54,797 shares of the company’s stock valued at $3,236,000 after buying an additional 43,490 shares during the last quarter. Invesco Ltd. lifted its position in shares of Tempus AI by 21.5% during the fourth quarter. Invesco Ltd. now owns 371,674 shares of the company’s stock valued at $21,947,000 after buying an additional 65,836 shares during the last quarter. Vident Advisory LLC boosted its holdings in shares of Tempus AI by 5.3% in the 4th quarter. Vident Advisory LLC now owns 10,376 shares of the company’s stock valued at $613,000 after buying an additional 522 shares in the last quarter. Finally, Oracle Investment Management Inc. purchased a new position in shares of Tempus AI in the 4th quarter worth approximately $384,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.